FIELD: bioengineering.
SUBSTANCE: claimed invention discloses the composition including the recombinant modified virus of the Ankara variolovaccine. Note here that the said recombinant modified virus of the Ankara variolovaccine is the EEV-type without directed infective specificity.
EFFECT: invention can be used in cancer or infectious disease treatment.
11 cl, 3 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD TO PRODUCE POX VIRUSES AND COMPOSITIONS OF POX VIRUSES | 2007 |
|
RU2489486C2 |
| METHOD OF OBTAINING POXVIRUSES AND COMPOSITIONS OF POXVIRUSES | 2007 |
|
RU2551982C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| POX VIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2557312C2 |
| COMPOSITIONS AND METHODS FOR INCREASING THE STABILITY OF TRANSGENES IN POXVIRUSES | 2017 |
|
RU2756534C2 |
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2508401C2 |
| ANTICANCER COMPOSITION | 2016 |
|
RU2728748C2 |
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2503717C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| IMMORTALISED CELL LINE OF BIRDS | 2008 |
|
RU2475536C2 |
